Exclusive Summary

• - Originator oprelvekin patents/data exclusivity expired long ago and active supply in US/EU is minimal, creating a favorable entry window.
• - Addresses a real need for over one million chemo patients annually with grade ≥3 thrombocytopenia, aiming to reduce transfusions and maintain dose intensity.
• - Not on WHO EML and not first-line in major guidelines, but offers a cost-effective, accessible option where TPO‑RAs are expensive or unavailable.
• - Global competition is sparse beyond China; position as a hospital supportive care and transfusion-sparing solution.
• - API meets USP/Ph. Eur. recombinant DNA technology chapters, with Distribution and Technology Transfer available to support local registration and compliance.

Asset Materials

Contact Us for Full Materials